Aggregates and proteostasis
The bulk of cellular functions are carried out by proteins. To maintain protein homeostasis (or proteostasis [1] ) -the state of proteome balance -mammalian cells must ensure that more than 10,000 different proteins fold and assemble efficiently upon synthesis and preserve their functionally active states in a wide range of environmental and metabolic conditions. This is a challenging task, since proteins are only marginally stable at physiological temperature and are constantly at risk of misfolding. In addition, the concentration and subcellular localization of each individual protein species needs to be carefully controlled. Proteostasis is maintained by a plethora of factors, including molecular chaperones and their regulators as well as the machineries of proteolytic degradation (~1400 proteins in mammalian cells [2, 3] ). An emerging concept of recent research is that these components function as a coordinated proteostasis network (PN). The organizational principle of this network is far from being understood but it is clear that the PN has evolved to ensure proteome integrity and prevent the accumulation of aberrant conformational states, specifically protein aggregates, which are increasingly recognized as the cause of cytotoxicity in neurodegenerative diseases and other medical disorders, ranging from Alzheimer's disease (AD) to type 2 diabetes [4] .
We define a protein aggregate as any association of two or more protein molecules in a non-native conformation. Aggregates cover a range of structures, from amorphous assemblies to highly ordered fibrils (amyloid) with cross-β-structure. The propensity of a specific protein to aggregate is governed primarily by the chemical properties of its amino acid sequence, the conformational stability of its folded state and its cellular concentration [5, 6] . The extremely high total protein concentration in cells (~300 g/L) results in excluded volume effects (macromolecular crowding) and substantially increases the tendency of non-native protein molecules to aggregate compared to dilute solutions [7] . Moreover, ~30% of proteins in higher eukaryotes contain extensive intrinsically unstructured regions (>30 amino acids in length) [8] .
These proteins are often metastable and some of them are particularly toxic when they aggregate, like α-synuclein in Parkinson's disease (PD) and Aβ and Tau in AD. The presence of aggregates is indicative of proteostasis imbalance. However, aggregate formation is not only the result of insufficient proteostasis capacity, but can also be the cause of PN imbalance by overburdening available chaperone and degradation machineries, thereby enforcing a self-propagating cycle that eventually leads to proteostasis collapse and cell death (Figure 1 ).
In this review we summarize recent research addressing the interrelationship between protein aggregation and the functional status of the PN. We propose that the failure of cells to maintain proteostasis contributes to the toxic effects of protein aggregates in numerous diseases and is also a major driver of the aging process.
Correcting PN imbalance pharmacologically [2] presents an opportunity for the development of novel therapeutic strategies.
Components of the PN
While it has long been known that a large fraction of proteins require chaperone assistance for initial folding, we are only beginning to realize the extent to which proteins rely on chaperone-dependent functions throughout their cellular lifetime in order to maintain or regain their biologically active conformations [1, 3] . Core activities of the chaperone machinery include aggregation prevention (so-called 'holdase' function), the ability to refold aberrantly folded states, and also the capacity Protein synthesis and turnover must be carefully balanced and terminally misfolded proteins effectively removed by proteolysis to ensure proteostasis.
Clearance of misfolded proteins is mainly performed by the ubiquitin-proteasome system (UPS) (Figure 2 ), comprising more than 600 proteins in human cells [13, 14] .
Proteasome complexes are localized in the cytosol and nucleus. Proteins of the ER destined for degradation must first undergo retrotranslocation to the cytosol to gain access to the proteasome [15, 16] . Specific factors of the UPS cooperate closely with chaperone machinery. For example, the co-chaperone and ubiquitin ligase CHIP binds to Hsp70 and Hsp90, mediating ubiquitylation of faulty client proteins and guiding them to the proteasome [17] . Proteins that are unable to fold − due to mutation or amino acid misincorporation, or as a result of oxidative damage − will spend more time in the chaperone-bound state, thus increasing the chance of being recognized by CHIP and other ubiquitin ligases. Importantly, proteins need to be unfolded prior to proteasomal degradation in a reaction that is mediated by the AAA ATPase components of the proteasome complex [18] . For this mechanism to be efficient, proteins must be delivered in a soluble, non-aggregated state and incipient aggregates [19, 20] 
Age-dependent proteostasis decline
Age is the major risk factor for numerous aggregate deposition diseases, including AD, PD, Huntington's disease (HD) and other degenerative disorders. Studies in lower invertebrates such as the nematode C. elegans suggest that this is due to a decline in the capacity of aging cells and tissues to maintain proteostasis and to respond adequately to protein conformational stresses by upregulating PN machinery [31] [32] [33] . Whether an active aging program or simply lack of evolutionary pressure underlies this deterioration is unclear. It has been argued that organisms gained evolutionary advantage by devoting more resources to propagating the germ line than to maintaining the integrity of the somatic proteome ('disposable soma theory' [34]).
Indeed, in C. elegans proteostasis deteriorates dramatically soon after progeny have been produced [33] . It has also been suggested that pluripotent stem cells dedicate considerably more resources to proteome maintenance than differentiated cells [35] .
Although in mammals the age-dependent proteostasis decline is probably more 
Mechanisms of proteostasis impairment
Observations in cellular and organismal models indicate that the chronic production Much research in recent years has focused on understanding how protein aggregation interferes with the function of the UPS. Ubiquitin is present in the inclusions of nearly all neurodegenerative disease proteins, consistent with the view that these proteins fail to be degraded when they accumulate to levels that exceed proteasome capacity [56, 57] . A decline in proteasome activity during aging [58, 59] would explain why aging is a key risk factor for protein aggregation. Conversely, there is evidence that aggregation is not the result of a malfunctioning UPS but is actually its cause. This view is supported by findings that the expression of structurally unrelated aggregation-prone proteins prevents other proteins from being proteasomally degraded. Examples include polyQ-expansion proteins, the disease- as the uncoating of clathrin cages in endocytosis [74] . Notably, due to its high degree of interconnectedness and inbuilt redundancy, the PN is robust and able to buffer the deleterious consequences of aberrant protein species for long periods of time (up to decades in humans). However, when the network becomes critically overloaded, it can no longer stabilize its metastable, aggregation-prone clients (Figure 3) .
Consequently, these proteins will increasingly populate non-native states that would normally be degraded but now accumulate as ubiquitylated species in aggregates [61] .
When the network is overwhelmed, proteostasis collapse can be rapid and dramatic, as observed in the C. elegans model [33] . This loss of proteome stability contributes critically to cellular dysfunction and demise.
Mutations of PN components as cause for disease
The importance of proteostasis impairment in the pathogenesis of aggregate deposition disorders is reinforced by the existence of familial forms of neurodegeneration which are caused by mutation of PN components [75] . For example, loss-of-function mutations in the ubiquitin ligase PARKIN and the PARKIN-related kinase PINK1 are the cause of early-onset PD [76, 77] . PARKIN cooperates with PINK1 in the ubiquitylation and selective autophagy of mitochondria (mitophagy). Defects in this pathway result in accumulation of damaged mitochondria, disturbances in calcium homeostasis and oxidative stress [78] . The motor neuron disease ALS can also be caused by mutations in PN components.
Dominant mutations causing ALS have been mapped to several factors, including
ubiquilin-2, a protein that recruits proteasome complexes to ubiquitylated proteins;
sequestosome-1 (p62), a ubiquitin binding protein required for autophagy of aggregates; and VCP (p97/Cdc48), a AAA ATPase that functions in ERAD [79] .
Marinesco-Sjoegren syndrome, a rare autosomal recessive disorder characterized by cerebellar ataxia, is caused by loss of function mutations of the HSPA5 cochaperone SIL1, which is required for protein translocation and folding in the endoplasmic reticulum [80, 81] . Mutations of the mitochondrial chaperonin Hsp60 cause autosomal dominant spastic paraplegia [82] and an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy [83] .
The PN as a target for pharmacological intervention
The physiological regulation of the PN is complex and involves several interconnected pathways, some of which are inducible by cellular stress. These signaling pathways regulate specific transcriptional programs to adjust proteostasis capacity at the level of protein synthesis, folding and degradation machineries. [69, [88] [89] [90] and increase the formation of (presumably less toxic) inclusion bodies [51] . The chemical chaperone 4-phenylbutyrate helps to restore ER proteostasis in metabolic diseases like type 2 diabetes [91] , and upregulation of ER folding capacity by activating the ER stress response can improve the secretion of certain disease proteins such as mutant α1-antitrypsin and mitigate lysosomal enzyme deficiencies [92] .
Induction of the ER stress factor XBP1s can even prevent amyloid-β neurotoxicity in model systems for AD [93] . Phramacologically prolonging the transient attenuation of translation that occurs upon ER stress may be employed to adjust protein production rates to levels manageable by available chaperones [94] . Increasing proteolytic capacity provides an alternative approach to maintaining proteostasis. This may be achieved by induction of autophagy [95] or by inhibiting specific deubiquitinating enzymes, thereby increasing the rate at which the UPS clears misfolded proteins [96] .
Beyond counteracting the toxic effects of aggregating disease proteins, enhancing proteostasis capacity also extends lifespan and preserves the responsiveness of model organisms to acute stress [97] . Conversely, the chronic presence of aggregates can suppress the ability of cells to adequately respond to stress
[48], supporting the view that protein aggregation is a major driver of the aging process. Studies in mice showed that small molecule activators of the stress response, while effective early in disease, may lose efficacy during disease progression and aging [98] . On the other hand, sustained aggregate stress may result in a disproportionate response. For example, the long-term down-regulation of translation caused by chronic ER stress can be especially detrimental to neuronal cells [99, 100] which rely critically on ongoing translation for functionality. It will be crucial to unravel the mechanisms by which protein aggregation deregulates stress response pathways and undermines the cellular defense against toxic protein species. In any case, attempts to improve proteostasis pharmacologically would likely have to occur at an early stage of disease before the manifestation of severe cellular dysfunction.
Concluding remarks
Impairment of proteostasis is now being recognized as a basic mechanism by which chronic protein misfolding and toxic aggregation cause cellular dysfunction, [104] . The length of the expanded polyQ stretch (38-100 Q and more) correlates with increased aggregation propensity [105] and is inversely correlated with the age of disease onset [106] .
The formation of neuronal inclusions and toxic-gain-of-function pathology characteristic of HD can be reproduced in mouse models by expressing N-terminal fragments of huntingtin with an expanded polyQ tract [107] . Inclusions disappear when huntingtin expression is blocked [108] . 
Box 2: The nucleus as quality control compartment
The proteostasis machinery in the nucleus differs from that of the cytosol in that no protein synthesis takes place in this compartment. In contrast to protein transport into the ER or mitochondria, the nuclear pore complexes allow the import of proteins in their folded and assembled states. Besides specific roles in histone remodeling, the nuclear chaperone machinery is therefore mainly involved in conformational protein maintenance and in the degradation of misfolded proteins. The nucleus is highly enriched in proteasome complexes [111] and contains specific ubiquitin ligases dedicated to quality control [112, 113] . During stress, import of most proteins into the nucleus is reduced but additional chaperones and proteasome complexes enter using specific import factors [114] . A substantial fraction of nuclear proteins are metastable.
These proteins are conformationally destabilized upon stress and undergo proteasomal 
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